Eugenia Yazlovitskaya, PhD

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

1. Integrin alpha6 maintains the structural integrity of the kidney collecting system. Viquez OM, Yazlovitskaya EM, Tu T, Mernaugh G, Secades P, McKee KK, Georges-Labouesse E, De Arcangelis A, Quaranta V, Yurchenco P, Gewin LC, Sonnenberg A, Pozzi A, Zent R (2017) Matrix Biol : 244-257
   › Primary publication · 28043890 (PubMed) · PMC5330664 (PubMed Central)
2. Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design. Hargrove TY, Friggeri L, Wawrzak Z, Sivakumaran S, Yazlovitskaya EM, Hiebert SW, Guengerich FP, Waterman MR, Lepesheva GI (2016) J Lipid Res 57(8): 1552-63
   › Primary publication · 27313059 (PubMed) · PMC4959870 (PubMed Central)
3. Integrin α3β1 regulates kidney collecting duct development via TRAF6-dependent K63-linked polyubiquitination of Akt. Yazlovitskaya EM, Tseng HY, Viquez O, Tu T, Mernaugh G, McKee KK, Riggins K, Quaranta V, Pathak A, Carter BD, Yurchenco P, Sonnenberg A, Böttcher RT, Pozzi A, Zent R (2015) Mol Biol Cell 26(10): 1857-74
   › Primary publication · 25808491 (PubMed) · PMC4436831 (PubMed Central)
4. Cellular oxidative stress response mediates radiosensitivity in Fus1-deficient mice. Yazlovitskaya EM, Voziyan PA, Manavalan T, Yarbrough WG, Ivanova AV (2015) Cell Death Dis : e1652
   › Primary publication · 25695605 (PubMed) · PMC4669799 (PubMed Central)
5. A novel radioprotective function for the mitochondrial tumor suppressor protein Fus1. Yazlovitskaya EM, Uzhachenko R, Voziyan PA, Yarbrough WG, Ivanova AV (2013) Cell Death Dis : e687
   › Primary publication · 23788044 (PubMed) · PMC3702292 (PubMed Central)
6. CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds. Hargrove TY, Kim K, de Nazaré Correia Soeiro M, da Silva CF, Batista DD, Batista MM, Yazlovitskaya EM, Waterman MR, Sulikowski GA, Lepesheva GI (2012) Int J Parasitol Drugs Drug Resist : 178-186
   › Primary publication · 23504044 (PubMed) · PMC3596085 (PubMed Central)
7. Novel radiosensitizing anticancer therapeutics. Linkous AG, Yazlovitskaya EM (2012) Anticancer Res 32(7): 2487-99
   › Primary publication · 22753705 (PubMed)
8. Novel therapeutic approaches for targeting tumor angiogenesis. Linkous AG, Yazlovitskaya EM (2012) Anticancer Res 32(1): 1-12
   › Primary publication · 22213282 (PubMed)
9. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. Schleicher SM, Thotala DK, Linkous AG, Hu R, Leahy KM, Yazlovitskaya EM, Hallahan DE (2011) PLoS One 6(7): e22182
   › Primary publication · 21799791 (PubMed) · PMC3140496 (PubMed Central)
10. Glycogen synthase kinase 3β inhibitors protect hippocampal neurons from radiation-induced apoptosis by regulating MDM2-p53 pathway. Thotala DK, Hallahan DE, Yazlovitskaya EM (2012) Cell Death Differ 19(3): 387-96
    › Primary publication · 21738215 (PubMed) · PMC3193912 (PubMed Central)
11. Angiogenesis in glioblastoma multiforme: navigating the maze. Linkous AG, Yazlovitskaya EM (2011) Anticancer Agents Med Chem 11(8): 712-8
    › Primary publication · 21707499 (PubMed)
12. Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer. Schulte RR, Linkous AG, Hallahan DE, Yazlovitskaya EM (2011) Cancer Lett 304(2): 137-43
    › Primary publication · 21397389 (PubMed) · PMC3075208 (PubMed Central)
13. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. Linkous AG, Yazlovitskaya EM, Hallahan DE (2010) J Natl Cancer Inst 102(18): 1398-412
    › Primary publication · 20729478 (PubMed) · PMC2943523 (PubMed Central)
14. Cytosolic phospholipase A2 as a mediator of disease pathogenesis. Linkous A, Yazlovitskaya E (2010) Cell Microbiol 12(10): 1369-77
    › Primary publication · 20642808 (PubMed)
15. A new class of molecular targeted radioprotectors: GSK-3beta inhibitors. Thotala DK, Geng L, Dickey AK, Hallahan DE, Yazlovitskaya EM (2010) Int J Radiat Oncol Biol Phys 76(2): 557-65
    › Primary publication · 20117291 (PubMed) · PMC2873869 (PubMed Central)
16. Interleukin-32 positively regulates radiation-induced vascular inflammation. Kobayashi H, Yazlovitskaya EM, Lin PC (2009) Int J Radiat Oncol Biol Phys 74(5): 1573-9
    › Primary publication · 19616744 (PubMed) · PMC2713876 (PubMed Central)
17. Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis. Thotala D, Chetyrkin S, Hudson B, Hallahan D, Voziyan P, Yazlovitskaya E (2009) Free Radic Biol Med 47(6): 779-85
    › Primary publication · 19540915 (PubMed) · PMC2739572 (PubMed Central)
18. Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. Linkous A, Geng L, Lyshchik A, Hallahan DE, Yazlovitskaya EM (2009) Clin Cancer Res 15(5): 1635-44
    › Primary publication · 19240173 (PubMed) · PMC2874582 (PubMed Central)
19. Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. Thotala DK, Hallahan DE, Yazlovitskaya EM (2008) Cancer Res 68(14): 5859-68
    › Primary publication · 18632640 (PubMed)
20. Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium. Yazlovitskaya EM, Linkous AG, Thotala DK, Cuneo KC, Hallahan DE (2008) Cell Death Differ 15(10): 1641-53
    › Primary publication · 18566601 (PubMed)
21. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Yazlovitskaya EM, Edwards E, Thotala D, Fu A, Osusky KL, Whetsell WO, Boone B, Shinohara ET, Hallahan DE (2006) Cancer Res 66(23): 11179-86
    › Primary publication · 17145862 (PubMed)
22. Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3beta in irradiated vascular endothelium. Tan J, Geng L, Yazlovitskaya EM, Hallahan DE (2006) Cancer Res 66(4): 2320-7
    › Primary publication · 16489037 (PubMed)
23. Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease. SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J, DeCarli C (2004) Neurobiol Aging 25(1): 63-9
    › Primary publication · 14675732 (PubMed)
24. Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. Yazlovitskaya EM, Persons DL (2003) Anticancer Res 23(3B): 2275-9
    › Primary publication · 12894503 (PubMed)
25. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. DeHaan RD, Yazlovitskaya EM, Persons DL (2001) Cancer Chemother Pharmacol 48(5): 383-8
    › Primary publication · 11761456 (PubMed)
26. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Yazlovitskaya EM, DeHaan RD, Persons DL (2001) Biochem Biophys Res Commun 283(4): 732-7
    › Primary publication · 11350044 (PubMed)
27. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal--regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC, Persons DL (2000) Mol Carcinog 29(4): 219-28
    › Primary publication · 11170260 (PubMed)
28. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. Persons DL, Yazlovitskaya EM, Pelling JC (2000) J Biol Chem 275(46): 35778-85
    › Primary publication · 10958792 (PubMed)
29. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC (1999) Clin Cancer Res 5(5): 1007-14
    › Primary publication · 10353733 (PubMed)
30. Association of apoptosis with the inhibition of extracellular signal-regulated protein kinase activity in the tumor necrosis factor alpha-resistant ovarian carcinoma cell line UCI 101. Yazlovitskaya EM, Pelling JC, Persons DL (1999) Mol Carcinog 25(1): 14-20
    › Primary publication · 10331740 (PubMed)

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword